Nanobiotix S.A.
NBTX
$51.50
-$3.57-6.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.74M | 2.76M | 14.15M | 13.12M | -9.47M |
| Total Other Revenue | 721.70K | 724.90K | 970.40K | 899.80K | 688.60K |
| Total Revenue | 3.47M | 3.48M | 15.12M | 14.02M | -8.78M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.47M | 3.48M | 15.12M | 14.02M | -8.78M |
| SG&A Expenses | 5.28M | 5.30M | 6.41M | 5.94M | 5.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.27M | 10.32M | 14.65M | 13.59M | 15.06M |
| Operating Income | -6.81M | -6.84M | 462.50K | 428.80K | -23.85M |
| Income Before Tax | -10.82M | -10.86M | -3.05M | -2.83M | -24.68M |
| Income Tax Expenses | -1.70K | -1.80K | 3.40K | 3.20K | -22.90K |
| Earnings from Continuing Operations | -10.81M | -10.86M | -3.05M | -2.83M | -24.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.81M | -10.86M | -3.05M | -2.83M | -24.66M |
| EBIT | -6.81M | -6.84M | 462.50K | 428.80K | -23.85M |
| EBITDA | -6.74M | -6.77M | 619.10K | 574.10K | -23.68M |
| EPS Basic | -0.22 | -0.23 | -0.06 | -0.06 | -0.52 |
| Normalized Basic EPS | -0.13 | -0.13 | -0.05 | -0.04 | -0.33 |
| EPS Diluted | -0.23 | -0.23 | -0.06 | -0.06 | -0.52 |
| Normalized Diluted EPS | -0.13 | -0.13 | -0.05 | -0.04 | -0.33 |
| Average Basic Shares Outstanding | 48.22M | 48.22M | 47.42M | 47.42M | 47.41M |
| Average Diluted Shares Outstanding | 48.22M | 48.22M | 47.42M | 47.42M | 47.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |